Document:

exhibit1010c

                                                                  Exhibit 10.10(c)                AMENDMENT NO. 1 TO ASSIGNMENT AGREEMENT   This Amendment No. 1 to Assignment Agreement (this “Amendment No. 1”) is entered into as   of December 4, 2019 (the “Effective Date”) between Daré Bioscience, Inc., (“Daré”), and  Hammock Pharmaceuticals, Inc., (“Hammock”).  WHEREAS, Daré and Hammock are parties to that Assignment Agreement entered into as of  December 5, 2018 (the “Agreement”).   WHEREAS, Daré and Hammock desire to amend the Agreement as stated herein.   NOW, THEREFORE, the parties hereto hereby agree as follows:   1.    Amendment to the Agreement. As of the Effective Date, Section 3.2 of the Agreement is  deleted in its entirety and replaced with the following:          “Deferred Fee.  On or before December 6, 2019, Daré shall pay Hammock in cash One         Hundred Twenty Five Thousand Dollars ($125,000).  Within two business days after        January 31, 2020, (such date, the “Deferred Payment Date”), Daré shall pay Hammock        One Hundred Twenty Five Thousand Dollars ($125,000) (the “Deferred Fee”) plus an        additional payment, in cash, of $12,500.  The Deferred Fee may be paid either (a) in cash        or (b) if Daré is then a publicly traded company, by delivery of freely transferrable shares        of common stock of Daré (the “Shares”), with such choice being made in the sole discretion        of Daré.  In the event that Daré elects to pay the Deferred Fee in Shares, the number of        Shares shall be determined by dividing $125,000 by the volume weighted average of the        sale price for Daré common stock on its primary trading exchange during the ten trading         day period immediately preceding the Deferred Payment Date; provided, however, that if         the number of shares issued to Hammock would require stockholder approval under         Nasdaq Rule 5635 (or any successor rule), then Daré may elect to deliver to Hammock that         number of shares of common stock as will not require stockholder approval and, for the         remainder, pay the cash value thereof based on the volume weight average sale price         referred to above.”      2.    Miscellaneous. Except as specifically provided in this Amendment No. 1, no other        amendments, revisions or changes are made to the Agreement. All other terms and        conditions of the Agreement remain in full force and effect, except that Section 6.5 of the        Agreement shall be deemed to incorporate this Amendment and Section 6.8 of the        Agreement shall not apply to this Amendment.  This Amendment No. 1 may be executed        in counterparts, each of which shall be deemed to be an original and all of which together        shall be deemed to be one and the same instrument. Delivery of an executed counterpart        of a signature page to this Amendment by facsimile or in electronic format (e.g., “pdf”)        or by other electronic means shall be effective as delivery of a manually executed        counterpart of this Amendment No. 1.  This Amendment may not be assigned by any        party separate and apart from the Agreement, but otherwise shall be binding and        assignable as provided in the Agreement.                                [Signature page follows]      ACTIVE/101640027.2  

 

IN WITNESS WHEREOF, the parties have executed this Amendment No. 1 as of the date first  written above.                                         COMPANY:                                                                                  Daré Bioscience, Inc.                                                                              By: /s/ SABRINA MARTUCCI JOHNSON                                          Name:  Sabrina Martucci Johnson                                   Title: President and CEO                                         December 18, 2019                                                                                    Hammock:                                                                                  Hammock Pharmaceuticals, Inc.                                                                                                                       By: /s/ WILLIAM R. MAICHLE                                                Name:  William R. Maichle                                   Title: President and CEO       ACTIVE/101640027.2exhibit1010d

                                                                                  Exhibit 10.10(d)                            AMENDMENT NO. 2 TO LICENSE AGREEMENT   This Amendment No. 2 to the License Agreement (this “Amendment No. 2”) is entered into as of  December 3, 2019 (the “Effective Date”) between Daré Bioscience, Inc., a Delaware corporation  (“Daré”), and TriLogic Pharma, LLC, a Delaware limited liability company (“TriLogic”), and MilanaPharm  LLC, a Delaware limited liability company (“MilanaPharm,” and individually and collectively with Trilogic  each a “Licensor” and together “Licensors”).  WHEREAS, Daré and Licensors are parties to that First  Amendment to License Agreement entered into as of December 5, 2018 (the “Agreement”).   WHEREAS, Daré and Licensors desire to amend the Agreement as stated herein.   NOW, THEREFORE, the parties hereto hereby agree as follows:   1.     Amendment to the Agreement. As of the Effective Date, Section 4.2.2 of the Agreement is deleted in its entirety and replaced with the following:          4.2.2   Additional Milestone Payment.  Subject to the terms and conditions set forth in this         Agreement, (i) on the First Amendment Date, Daré shall pay to MilanaPharm a payment of         Twenty-Five Thousand Dollars ($25,000); and (ii) within fifteen (15) days of the first to occur of (a)         the first (1st) anniversary of the First Amendment Date or (b) the closing of an equity financing         with a third party by Daré in which aggregate proceeds of at least Ten Million Dollars         ($10,000,000) are raised (such date, the “Deferred Payment Trigger Date”), Daré shall pay         MilanaPharm a fee of Two Hundred Thousand Dollars ($200,000) (the “Deferred Fee”).  The         Deferred Fee may be paid either (a) in cash or (b) by delivery of shares of Daré Common Stock,         with such choice being made in the sole discretion of Daré.  In the event that Daré elects to pay         the Deferred Fee in shares of Daré Common Stock, the number of shares of Daré Common         Stock shall be determined by dividing $200,000 by the average closing price of Daré common         stock for the five (5) trading day period immediately preceding the Deferred Payment Trigger         Date.  For the purposes of the Deferred Fee, “Daré Common Stock” means shares of common         stock, $0.0001 par value per share, of Daré that have been registered on a Form S-1 or Form S-3         and are eligible for trading on the NASDAQ and that when issued are duly authorized, validly         issued, fully paid, and non-assessable, not subject to any pre-emptive rights, and freely tradeable         by MilanaPharm on the NASDAQ upon delivery to MilanaPharm.  In the event Daré elects to pay         the Deferred Fee in cash, up to but not exceeding half of the Deferred Fee (up to but not         exceeding $100,000) (the “Deferred Fee Balance”) may be paid within fifteen (15) days of         January 31, 2020.  In addition to the Deferred Fee Balance, a penalty charge of ten percent         (10%) of the Deferred Fee Balance will also be due within fifteen (15) days of January 31, 2020.          For example, if the Deferred Fee Balance is $100,000, a penalty charge of $10,000 will also be         payable, such that the total amount due is $110,000. Any failure to pay the milestone payment set         forth herein when due shall constitute a breach of a payment obligation entitling MilanaPharm to         proceed to terminate this Agreement in its entirety for breach pursuant to the terms of Section         12.2 of the Agreement.    2.     Miscellaneous. Except as specifically provided in this Amendment No. 1, no other amendments,        revisions or changes are made to the Agreement. All other terms and conditions of the        Agreement remain in full force and effect. This Amendment No. 1 may be attached to and shall        form a part of the Agreement. This Amendment No. 1 may be executed in counterparts, each of        which shall be deemed to be an original and all of which together shall be deemed to be one and        the same instrument. Delivery of an executed counterpart of a signature page to this Amendment

 

       by facsimile or in electronic format (e.g., “pdf”) or by other electronic means shall be effective as         delivery of a manually executed counterpart of this Amendment No. 1. This Amendment No. 1 will         be binding upon and inure to the benefit of the parties hereto and their respective heirs,         executors, personal representatives, successors and permitted assigns.                                         [Signature page follows]                                                    2  4841-6733-9641, v. 1 

 

IN WITNESS WHEREOF, the parties have executed this Amendment No. 1 as of the date first written  above.       Daré Bioscience, Inc.                   Trilogic Pharma, LLC   By: /s/ SABRINA MARTUCCI JOHNSON        By: /s/ JAMES HARWICK   Print Name: Sabrina Martucci Johnson    Print Name: James Harwick   Title: President and CEO                Title: CEO   Date: December 13, 2019                 Date: December 11, 2019                                              MilanaPharm LLC                            By: /s/ JAMES HARWICK                      Print Name: James Harwick                  Title: CEO                                 Date: December 11, 2019daio_ex4-6

 

EXHIBIT 4.6

DATA I/O CORPORATION

DESCRIPTION OF DATA I/O CORPORATION’S COMMON
STOCK

 

 

The
common stock of Data I/O Corporation is its only class of
securities registered under Section 12 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”).

 

The
following description of our Common Stock is a summary and does not
purport to be complete. It is subject to and qualified in its
entirety by reference to our Restated Articles of Incorporation and
Certificate of Designation, Preferences and Rights of Series A
Junior Participating Preferred Stock (the “Articles”) and our Amended and
Restated Bylaws (the “Bylaws”), each of which attached
as exhibit to the Annual Report on Form 10-K. We are incorporated
in the State of Washington and are subject to the Washington
Business Corporation Act, Title 23B of the Revised Code of
Washington.

 

Authorized Capital Shares

 

Our
authorized capital shares are thirty-five million (35,000,000),
consisting of thirty million (30,000,000) shares of Common Stock
(“Common
Stock”), and five million (5,000,000) shares of
Preferred Stock. Two hundred thousand (200,000) shares of Series A
Junior Participating Preferred Stock have been designated. The
outstanding shares of our Common Stock are fully paid and
nonassessable. There are no shares of Preferred Stock
outstanding.

 

Voting Rights

 

Holders
of Common Stock are entitled to one vote per share on all matters
voted on by the shareholders, including the election of directors.
Our Common Stock does not have cumulative voting
rights.

 

Dividend Rights

 

The
holders of Common Stock are entitled to receive dividends, if any,
as may be declared from time to time by the Board of Directors in
its discretion out of funds legally available for the payment of
dividends.

 

Liquidation Rights

 

Holders
of Common Stock will share ratably in all assets legally available
for distribution to our shareholders in the event of
dissolution.

 

Other Rights and Preferences

 

Our
Common Stock has no sinking fund or redemption provisions or
preemptive, conversion or exchange rights. Holders of Common Stock
may act by unanimous written consent.

 

Potential Limitations on Rights of Holders of Common
Stock

 

Our
Articles authorize our board of directors to issue up to 5,000,000
shares of Preferred Stock and to determine the price, rights,
preferences, privileges and restrictions, including voting rights,
of those shares without any further vote or action by the
shareholders. Two hundred thousand (200,000) shares of Series A
Junior Participating Preferred Stock have been designated, but none
are outstanding. The rights of the holders of Common Stock may be
subject to, and may be adversely affected by, the rights of the
holders of any Preferred Stock that may be issued in the
future.

 

Listing

 

The
Common Stock is traded on The Nasdaq Stock Market LLC under the
trading symbol “DAIO.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]